Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Alberta Cancer Exercise Dose in Colorectal Cancer

NCT07913906 is registered in ClinicalTrials.gov with University of Calgary as lead sponsor.

NCT NCT07913906 Not yet recruiting Phase 2 90 participants (estimated) Started 2027 1 site

Follow this trial by email Email me the PDF

Get the NCT07913906 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Summary

Not yet recruiting, started January 2027. Interventional study, Phase 2, 90 participants (estimated). Lead sponsor University of Calgary; Canada. Primary measure: Proportion of patients in the once per week and twice per week group that achieve an increase of ≥10...

How it compares

1,318 similar trials: same condition (Colorectal Neoplasms) and phase

Enrollment

This trial
90
Middle half
27 to 100
Median
50
Trials with a value
1,266

Months from start to completion

This trial
24
Middle half
27 to 60.4
Median
39
Trials with a value
1,244

Sites

This trial
1
Middle half
1 to 8
Median
1
Trials with a value
1,203
Posted results or a linked paper 44% 583 of 1,318 similar trials; this trial: no

Registry record

As filed in ClinicalTrials.gov.

Title
Alberta Cancer Exercise Dose in Colorectal Cancer
Lead sponsor
University of Calgary
Phase
Phase 2
Overall status
Not yet recruiting
Start date
January 31, 2027
Completion date
January 31, 2029
Enrollment
90 (estimated)
Sites
1

Conditions

MeSH condition names; the registry's own terms follow.

Colorectal Neoplasms, Neoplasms

Registry terms: cancer, colorectal cancer

Who could take part, where it ran, who ran it

As filed in ClinicalTrials.gov.

Sex
All
Minimum age
18 Years
Healthy volunteers
No
Study type
Interventional
Sites
1
Countries
Canada
Lead sponsor
University of Calgary

Arms

As registered; 3 arms.

Registered arms
Arm Type Interventions
Once/week exercise session for 12 weeks (Arm 1) Experimental Group Exercise Classes - Arm 1
Show registry wording

Arm 1 will be supervised by a CEP once a week (e.g. Tuesday or Thursday) at the ACCCC. The exercise program includes aerobic, strength and balance / flexibility exercises for 12 week.

Twice/week exercise session for 12 weeks (Arm 2) Active comparator Group Exercise Classes - Arm 2
Show registry wording

Arm 2 will be supervised by a CEP twice a week (e.g. Tuesday and Thursday) at the ACCCC. The exercise program includes aerobic, strength and balance / flexibility exercises for 12 week.

Control-waitlisted group (Arm 3) No intervention
Show registry wording

Standard of care control-waitlisted group to start the Thrive program after 24 weeks on a voluntary basis

Primary endpoints

Registered primary outcome measures; 1 primary.

Registered primary endpoints
Measure Time frame
Proportion of patients in the once per week and twice per week group that achieve an increase of ≥10 MET-h/wk of total physical activity level at 12 weeks. Single time point: 12 weeks
Show registry wording

To assess the dose-response effect of exercise frequency (once versus twice weekly) over a 12-week period on clinically meaningful improvements in physical activity level (≥10 MET-h/wk increase over baseline) in patients with early-stage CRC receiving systemic treatment, with the goal of identifying the minimal effective intervention frequency

Lead sponsor's other trials

University of Calgary, most recent start first.

Similar trials

Same condition (Colorectal Neoplasms) and phase, most recent start first.